HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $75

-5.94% Pre

Structure Therapeutics, Inc.

GPCR

0.00

HC Wainwright & Co. analyst Andrew Fein maintains Structure Therapeutics (NASDAQ: GPCR) with a Buy and lowers the price target from $80 to $75.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Protara Therapeutics Announces It Achieves Clinical Success With One Or Two Doses Of TARA-002 In Phase 2 STARBORN-1 Study In 88% Of Participants' No Serious Adverse Events Seen

Painful week for individual investors invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) after 11% drop, institutions also suffered losses

Arrowhead Pharmaceuticals (ARWR): Assessing Valuation After FDA Greenlight for First siRNA Therapy REDEMPLO

Abbott Signs Agreement To Acquire Exact Sciences For $105/Share At ~$20B Equity Value

BriaCell Therapeutics' Unit Partners With Research.AI To Design Anti-Cancer Isoform-selective Kinase Inhibitors

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Pasithea Therapeutics Announces Phase 1 Data From Its Ongoing First-In-Human Trial Evaluating PAS-004; Partial Response Observed In A MEK-Rechallenge 3rd-line Melanoma Patient With Braf V600e Mutation Who Remains On Trial For More Than 11 Months; ...

Reported Earlier, Mesoblast And BMT CTN Launch Pivotal Trial Of Ryoncil For Adults With Grade III IV Severe SR aGvHD